tbuckley/cabot-search huggingface dataset:
TCT-265 Impact of Peri-procedural Complications on Mortality and Quality of Life after TAVR
Authors: Suzanne Arnold, Yiran Zhang, Suzanne Baron, Thomas McAndrew, Maria Alu, Susheel Kodali, Samir Kapadia, Vinod Thourani, D. Craig Miller, Michael Mack, Martin Leon, David Cohen
Journal: Journal of the American College of Cardiology (2017)
Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)
Authors: Michael Wang, Stephen J. Schuster, Tycel Phillips, Izidore S. Lossos, Andre Goy, Simon Rule, Mehdi Hamadani, Nilanjan Ghosh, Craig B. Reeder, Evelyn Barnett, Marie-Laure Casadebaig Bravo, Peter Martin
Journal: Journal of Hematology & Oncology (2017)

The observational MCL-004 study evaluated outcomes in patients with relapsed/refractory mantle cell lymphoma who received lenalidomide-based therapy after ibrutinib failure or intolerance. The primary endpoint was investigator-assessed overall response rate based on the 2007 International Working Group criteria. Of 58 enrolled patients (median age, 71 years; range, 50-89), 13 received lenalidomide monotherapy, 11 lenalidomide plus rituximab, and 34 lenalidomide plus other treatment. Most patients (88%) had received ≥ 3 prior therapies (median 4; range, 1-13). Median time from last dose of ibrutinib to the start of lenalidomide was 1.3 weeks (range, 0.1-21.7); 45% of patients had partial responses or better to prior ibrutinib. Primary reasons for ibrutinib discontinuation were lack of efficacy (88%) and ibrutinib toxicity (9%). After a median of two cycles (range, 0-11) of lenalidomide-based treatment, 17 patients responded (8 complete responses, 9 partial responses), for a 29% overall response rate (95% confidence interval, 18-43%) and a median duration of response of 20 weeks (95% confidence interval, 2.9 to not available). Overall response rate to lenalidomide-based therapy was similar for patients with relapsed/progressive disease after previous response to ibrutinib (i.e., ≥PR) versus ibrutinib-refractory (i.e., ≤SD) patients (30 versus 32%, respectively). The most common all-grade treatment-emergent adverse events after lenalidomide-containing therapy (n = 58) were fatigue (38%) and cough, dizziness, dyspnea, nausea, and peripheral edema (19% each). At data cutoff, 28 patients have died, primarily due to mantle cell lymphoma. Lenalidomide-based treatment showed clinical activity, with no unexpected toxicities, in patients with relapsed/refractory mantle cell lymphoma who previously failed ibrutinib therapy. Clinicaltrials.gov identifier NCT02341781 . Date of registration: January 14, 2015.
Fièvre hémorragique avec syndrome rénal: analyse des épisodes en Belgique, en France, en Allemagne, aux Pays-Bas et au Luxembourg en 2005
Authors: P Heyman, C Cochez, G Ducoffre, A Mailles, H Zeller, M Abu Sin, J Koch, G van Doornum, M Koopmans, J Mossong, F Schneider
Journal: Eurosurveillance (2007)

Cet article a pour but de decrire la situation en 2005 par rapport a la fievre hemorragique avec syndrome renal (FHSR) dans cinq pays voisins (Belgique, France, Allemagne, Pays-Bas et Luxembourg) et de definir les zones les plus touchees.
Actividades e resultados do EARSS: actualização
Authors: U Buchholz, S L A M Bronzwaer, P Schrijnemakers, J Monen, J. L. Kool
Journal: Eurosurveillance (2001)

Os ultimos resultados do EARSS (1990–2000) sugerem que as taxas de S. aureus resistente a meticilina e S. pneumoniae nao sensivel a penicilina sao mais elevadas nos paises do Sul da Europa do que nos paises do Norte da Europa. As criancas jovens e os idosos sao os grupos etarios que apresentam maior risco de uma infeccao pelo PNSP. O risco de infeccao com o S. aureus resistente a meticilina aumenta com a idade; os doentes hospitalizados em unidades de cuidados intensivos estao mais expostos a esse risco.
Bilateral optic neuropathy related to severe anemia in a patient with alcoholic cirrhosis: a case report and review of the literature
Authors: Lisa Humbertjean-Selton, Jérôme Selton, Nolwenn Riou-Comte, Jean-Christophe Lacour, Gioia Mione, Sébastien Richard
Journal: Clinical and Molecular Hepatology (2017)

Anemia appears frequently in patients with alcoholic liver disease (ALD) but has never been linked to bilateral nonarteritic anterior ischemic optic neuropathy (NAION). A 65-year-old woman with a medical history of alcoholic cirrhosis was admitted for bilateral NAION. On admission, she was found to have a low arterial pressure and severe normocytic anemia (48 g/L). The anemia was related to chronic bleeding due to antral gastritis along with other factors associated with ALD. The applied treatment consisted of urgent transfusion followed by high doses of proton-pump inhibitors, iron and vitamin supplementation, and support in lifestyle measures. Her hemoglobin levels remained stable after 2 years but the patient still suffered from visual loss. This case highlights the link between anemia and bilateral NAION in ALD patients. The optic nerve head is prone to infarction in this context due to the vascularization characteristics of ALD. Hemoglobin levels should be monitored in ALD patients to avoid the severe complication of NAION.
Regional Delivery of Chimeric Antigen Receptor–Engineered T Cells Effectively Targets HER2+ Breast Cancer Metastasis to the Brain
Authors: Saul J. Priceman, Dileshni Tilakawardane, Brook Jeang, Brenda Aguilar, John P. Murad, Anthony K. Park, Wen-Chung Chang, Julie R. Ostberg, Josh Neman, Rahul Jandial, Jana Portnow, Stephen J. Forman, Christine E. Brown
Journal: Clinical Cancer Research (2017)

Purpose: Metastasis to the brain from breast cancer remains a significant clinical challenge, and may be targeted with CAR-based immunotherapy. CAR design optimization for solid tumors is crucial due to the absence of truly restricted antigen expression and potential safety concerns with "on-target off-tumor" activity. Here, we have optimized HER2-CAR T cells for the treatment of breast to brain metastases, and determined optimal second-generation CAR design and route of administration for xenograft mouse models of breast metastatic brain tumors, including multifocal and leptomeningeal disease.Experimental Design: HER2-CAR constructs containing either CD28 or 4-1BB intracellular costimulatory signaling domains were compared for functional activity in vitro by measuring cytokine production, T-cell proliferation, and tumor killing capacity. We also evaluated HER2-CAR T cells delivered by intravenous, local intratumoral, or regional intraventricular routes of administration using in vivo human xenograft models of breast cancer that have metastasized to the brain.Results: Here, we have shown that HER2-CARs containing the 4-1BB costimulatory domain confer improved tumor targeting with reduced T-cell exhaustion phenotype and enhanced proliferative capacity compared with HER2-CARs containing the CD28 costimulatory domain. Local intracranial delivery of HER2-CARs showed potent in vivo antitumor activity in orthotopic xenograft models. Importantly, we demonstrated robust antitumor efficacy following regional intraventricular delivery of HER2-CAR T cells for the treatment of multifocal brain metastases and leptomeningeal disease.Conclusions: Our study shows the importance of CAR design in defining an optimized CAR T cell, and highlights intraventricular delivery of HER2-CAR T cells for treating multifocal brain metastases. Clin Cancer Res; 24(1); 95-105. ©2017 AACR.
Aspiration Incidentally Detected by a Meckel Scintigraphy
Authors: Xia Bai, Johannes C. Fostitsch, Hongming Zhuang
Journal: Clinical Nuclear Medicine (2017)

Meckel scintigraphy with Tc-pertechnetate was performed in a 5-year-old boy to determine whether a Meckel diverticulum containing ectopic gastric mucosa caused bleeding. The images did not reveal focal activity characteristic of a Meckel diverticulum. Unexpectedly, activity in the tracheobronchial tree was visualized, consistent with aspiration of the radioactive saliva.
Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma
Authors: Keisuke Kataoka, Masako Iwanaga, Jun-ichirou Yasunaga, Yasunobu Nagata, Akira Kitanaka, Takuro Kameda, Makoto Yoshimitsu, Yuichi Shiraishi, Aiko Sato-Otsubo, Masashi Sanada, Kenichi Chiba, Hiroko Tanaka, Yotaro Ochi, Kosuke Aoki, Hiromichi Suzuki, Yusuke Shiozawa, Tetsuichi Yoshizato, Yusuke Sato, Kenichi Yoshida, Kisato Nosaka, Masakatsu Hishizawa, Hidehiro Itonaga, Yoshitaka Imaizumi, Wataru Munakata, Kotaro Shide, Yoko Kubuki, Tomonori Hidaka, Tsuyoshi Nakamaki, Ken Ishiyama, Shuichi Miyawaki, Ryohei Ishii, Osamu Nureki, Kensei Tobinai, Yasushi Miyazaki, Akifumi Takaori-Kondo, Tatsuhiro Shibata, Satoru Miyano, Kenji Ishitsuka, Atae Utsunomiya, Kazuya Shimoda, Masao Matsuoka, Toshiki Watanabe, Seishi Ogawa
Journal: Blood (2017)
Chemical Profiling of Primary Mesothelioma Cultures Defines Subtypes with Different Expression Profiles and Clinical Responses
Authors: Laurel M. Schunselaar, Josine M.M.F. Quispel-Janssen, Yongsoo Kim, Constantine Alifrangis, Wilbert Zwart, Paul Baas, Jacques Neefjes
Journal: Clinical Cancer Research (2017)

Purpose: Finding new treatment options for patients with malignant pleural mesothelioma is challenging due to the rarity and heterogeneity of this cancer type. The absence of druggable targets further complicates the development of new therapies. Current treatment options are therefore limited, and prognosis remains poor.Experimental Design: We performed drug screening on primary mesothelioma cultures to guide treatment decisions of corresponding patients that were progressive after first- or second-line treatment.Results: We observed a high concordance between in vitro results and clinical outcomes. We defined three subgroups responding differently to the anticancer drugs tested. In addition, gene expression profiling yielded distinct signatures that segregated the differently responding subgroups. These genes signatures involved various pathways, most prominently the fibroblast growth factor pathway.Conclusions: Our primary mesothelioma culture system has proved to be suitable to test novel drugs. Chemical profiling of primary mesothelioma cultures allows personalizing treatment for a group of patients with a rare tumor type where clinical trials are notoriously difficult. This personalized treatment strategy is expected to improve the poor prospects of patients with mesothelioma. Clin Cancer Res; 24(7); 1761-70. ©2017 AACRSee related commentary by John and Chia, p. 1513.
First results of COSTAR: A randomised trial of 3-dimensional conformal radiotherapy (3DCRT) vs cochlea-sparing intensity modulated radiotherapy (CS-IMRT) in patients with parotid cancer.
Authors: Christopher Nutting, James P Morden, Matthew Beasley, Shreerang Bhide, Marie Emson, Mererid Evans, Lydia Fresco, Dorothy M. Gujral, Kevin J. Harrington, Catherine Lemon, Rekha Neupane, Kate Newbold, Robin Prestwich, Martin Robinson, Paul Sanghera, Mutiah Sivaramalingam, Mark Adrian Sydenham, Emma Wells, Stephanie Witts, Emma Hall
Journal: Journal of Clinical Oncology (2016)

6006 Background: 30-50% of patients receiving post-operative RT for parotid cancer experience ipsilateral hearing loss. IMRT can reduce radiation dose to the cochlea. COSTAR (CRUK/08/004) investigated the role of IMRT in reducing hearing loss in these patients. Methods: Patients with histologically confirmed carcinoma of the parotid gland (pT1-4, pN0-3, M0) were randomized 1:1 to receive CT-planned 3DCRT or CS-IMRT. 60Gy (R0 resection) or 65Gy (R1-2) in 30 fractions were delivered over 6 weeks. Treatment allocation used minimisation, balancing for centre and planned RT dose. The primary endpoint was proportion of patients with hearing loss in the ipsilateral cochlea of ≥10dB measured by bone conduction at 4000Hz 12 months (m) after RT; compared between randomized groups by an exact test (α=0.05). Secondary endpoints (α=0.01) included hearing loss at 6m and 24m, vestibular function, acute and late toxicity, patient reported quality of life (including Glasgow Hearing Aid Benefit Profile (GHABP), time to tumour recurrence and survival. Results: 110 patients (54 3DCRT; 56 CS-IMRT) were randomised between 2008 and 2013 from 22 UK centres. 99 (90%) patients were R1-2 (47 3DCRT; 52 CS-IMRT). Mean dose to the ipsilateral cochlea was 56.2Gy for 3DCRT and 35.7Gy for CS-IMRT, (p<0.001). 66/110 (60%) patients were evaluable for the primary endpoint; the main reasons for non-evaluability were non-attendance at follow-up audiology and bone conduction assessment not performed. At 12m, a loss of ≥10dB in ipsilateral bone conduction was observed in 14/35 (40%) 3DCRT and 11/31 (36%) CS-IMRT patients (p=0.80). No statistically significant differences in bone or air conduction were observed at 6m or 24m after RT nor for any GHABP initial disability or handicap subscales, vestibular function, acute or late toxicity, overall quality of life, time to tumour recurrence or survival. Conclusions: IMRT reduced the radiation dose below the accepted tolerance of the cochlea, but this did not lead to a statistically significant reduction in the proportion of patients with hearing loss in the ipsilateral ear at 12 months after RT. Clinical trial information: ISRCTN81772291.
Material-induced Senescence (MIS): Fluidity Induces Senescent Type Cell Death of Lung Cancer Cells via Insulin-Like Growth Factor Binding Protein 5
Authors: Sharmy Saimon Mano, Koichiro Uto, Mitsuhiro Ebara
Journal: Theranostics (2017)

Objective:We propose here material-induced senescence (MIS) as a new therapeutic concept that limits cancer progression by stable cell cycle arrest.This study examined for the first time the effect of material fluidity on cellular senescence in lung carcinoma using poly(ε-caprolactone-co-D, L-lactide) (P(CL-co-DLLA)) with tunable elasticity and fluidity.Methods: The fluidity was varied by chemically crosslinking the polymer networks: the crosslinked P(CL-co-DLLA) shows solid-like properties with a stiffness of 260 kPa, while the non-crosslinked polymer exists in a quasi-liquid state with loss and storage moduli of 33 kPa and 11 kPa, respectively.Results: We found that cancer cells growing on the non-crosslinked, fluidic substrate undergo a non-apoptotic form of cell death and the cell cycle was accumulated in a G0/G1 phase.Next, we investigated the expression of biomarkers that are associated with cancer pathways.The cancer cells on the fluidic substrate expressed several biomarkers associated with senescence such as insulin-like growth factor binding protein 5 (IGFBP5).This result indicates that when cancer cells sense fluidity in their surroundings, the cells express IGFBP5, which in turn triggers the expression of tumor suppressor protein 53 and initiates cell cycle arrest at the G1 phase followed by cellular senescence.Furthermore, the cancer cells on the fluidic substrate maintained their epithelial phenotype, suggesting that the cancer cells do not undergo epithelial to mesenchymal transition.Conclusion: By considering these results as the fundamental information for MIS, our system could be applied to induce senescence in treatment-resistant cancers such as metastatic cancer or cancer stem cells.
Therapeutic application of linked color imaging for colorectal endoscopic mucosal resection
Authors: Yasuhiro Goda, Hirohito Mori, Hideki Kobara, Noriko Nishiyama, Nobuya Kobayashi, Tatsuo Yachida, Tsutomu Masaki
Journal: Endoscopy (2017)

Linked color imaging (LCI; Fujifilm Co., Tokyo, Japan) is a newly developed image-enhanced technique that has shown high diagnostic performance in the field of gastrointestinal endoscopy. LCI enhances color separation of the mucosal layer, making red regions redder and white regions whiter. This contributes to the detection of gastric cancer [1], ulcerative colitis [2], colorectal polyps [3] [4], and other lesions. Although the diagnostic productivity is steadfast, the treatment benefit of LCI remains unclear or limited [5]. We herein introduce an advantage of LCI with respect to increasing the safety of endoscopic mucosal resection (EMR), illustrating the efficacy of LCI in the treatment field.
Challenges in Measuring the Affordability of US Health Care
Authors: Joseph Antos, James C. Capretta
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Platelets from donors with consistently low HLA-B8, -B12, or -B35 expression do not undergo antibody-mediated internalization
Authors: Anno Saris, Bert Tomson, Anneke Brand, Arend Mulder, Frans H. Claas, Jos Lorinser, John Scharenberg, S. Marieke van Ham, Anja ten Brinke, Jaap Jan Zwaginga, Pieter F. van der Meer
Journal: Blood (2017)
Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy
Authors: Stuart K. Roberts, Ricky Lim, Simone Strasser, Amanda Nicoll, Alessia Gazzola, Joanne Mitchell, Way Siow, Tiffany Khoo, Zaki Hamarneh, Martin Weltman, Paul Gow, Natasha Janko, Edmund Tse, Gauri Mishra, En-Hsiang Cheng, Miriam Levy, Wendy Cheng, Siddharth Sood, Richard Skoien, Jonathan Mitchell, Amany Zekry, Jacob George, Gerry MacQuillan, Alan Wigg, Katherine Stuart, William Sievert, Geoffrey McCaughan
Journal: Clinical Gastroenterology and Hepatology (2017)
Colorectal cancer in inflammatory bowel disease combined therapy results.
Authors: Olexandr Borota, Oleksandr Borota, German Polunin, Ivan Plakhotnikov
Journal: Journal of Clinical Oncology (2014)

e14645 Background: Colorectal cancer (CRC) is a severe complication of inflammatory bowel disease (IBD) and causes up to 10-15% of all deaths in this patients group. Five-year survival is only up to 31-43%. Data on preoperative radiotherapy efficiency and safety in this patient’s cohort are not studied enough. Methods: A total of 1,098 patient with IBD were enrolled in this study: 758 (69.03%) ulcerative colitis (UC) and 340 (30.97%) Crohn’s disease (CD) cases. IBD-associated CRC appeared in 43 (3.92%) cases: 30 (69.77%) in UC (middle age 55.7±4.3 years) and 13 (30.23%) in CD (middle age 51.1±3.1 years) patients. CRC stage was I-II in 31 (72.09%) and III – in 12 (27.91%) cases. Bowel affected was: sigmoid – 17 (39.53%), rectum – 12 (27.91%), caecum – 5 (11.63%), and transverse – 1 (2.33%). In 8 (18.6%) cases multiple neoplasms were found. Results: Eight (66.67%) of 12 patients with rectal primaries recieved preoperative radiotherapy in a total dose of 25 Gy within five days; four (33.33%) patients refused preoperative radiotherapy due to high complication risk. There were 43 (95.56%) of 45 patients who underwent different types of bowel resections: 22 (51.16%) elective and 21 (48.84%) urgent surgeries; 36 (83.72%) R0 and seven (16.28%) R2 resections. Early complications occurred in six (13.95%) patients. Post-operative mortality rate was 4.65%. Average age at death was 48.0±5.1 years. Adjuvant chemotherapy was administered in accordance to standards. Overall five-year survival for I-II stages was 55.4%, for III stage – 33.2%. Conclusions: Surgery followed by adjuvant chemotherapy seems to be the most rational method of IDB-associated CRC complex treatment. Neoadjuvant radiotherapy should be strictly individually considered for IDB-associated rectal cancer patients due to high complication risk.
The BRAIN Initiative Cell Census Consortium: Lessons Learned toward Generating a Comprehensive Brain Cell Atlas
Authors: Joseph R. Ecker, Daniel H. Geschwind, Arnold R. Kriegstein, John Ngai, Pavel Osten, Damon Polioudakis, Aviv Regev, Nenad Sestan, Ian R. Wickersham, Hongkui Zeng
Journal: Neuron (2017)
Passive smoking in relation to lung cancer incidence and histologic types in Norwegian adults: the HUNT study
Authors: Yi-Qian Sun, Yue Chen, Arnulf Langhammer, Frank Skorpen, Chunsen Wu, Xiao-Mei Mai
Journal: European Respiratory Journal (2017)

Passive smoking has been proposed as a risk factor for lung cancer. The increased risks for lung cancer overall and different histologic types in relation to passive smoking were demonstrated in two meta-analytical studies [1, 2], in which the included studies were mostly case–control designs, which are subject to recall bias. To date, there have been a limited number of prospective studies on passive smoking in relation to lung cancer incidence, most of which included only never-smoking women [3–5]. There is also a lack of longitudinal investigations concerning the influence of passive smoking on different histologic types of lung cancer. We aimed to evaluate the influences of passive smoking during childhood and adulthood on the development of lung cancer and histologic types in a long-term follow-up cohort, and to assess possible sex-related differences in the association. Childhood and adulthood exposure to passive smoking associated with increased risk of lung cancer <http://ow.ly/7kXN30f6aZu> The Nord-Trøndelag Health Survey (HUNT) is a collaboration between the HUNT Research Centre (Faculty of Medicine and Health Sciences, NTNU, Norwegian University of Science and Technology), the Nord-Trøndelag County Council and the Norwegian Institute of Public Health. Author contributions: YQS, AL, YC and XMM contributed to the study design. XMM and AL contributed to data collection. CW contributed to statistical analyses. YQS conducted statistical analyses, interpreted results and wrote the initial draft of the manuscript. AL, FS, CW, YC and XMM participated in the data interpretation and helped to write the final draft of the manuscript.
Adjuvant Capecitabine in Triple Negative Breast Cancer with Residual Tumor after Neoadjuvant Chemotherapy: A Case Series
Authors: Miyuki Uchiyama, Hiromichi Nakajima, Jun Masuda, Yukinori Ozaki, Chihiro Kondo, Yuko Tanabe, Toshimi Takano, Takuya Ogura, Nobuko Tamura, Hidetaka Kawabata
Journal: Annals of Oncology (2017)
TCT-7 COOL AMI Pilot - randomized controlled trial of intravascular therapeutic hypothermia (TH) in conscious anterior ST-elevation myocardial infarction (STEMI). Cardiac magnetic resonance (cMR) imaging results of microvascular obstruction (MVO) and ejection fraction (EF) at 4-6 and 30 days
Authors: Thomas Keeble, Marko Noc, Grigoris Karamasis, Beata Sredniawa, David Erlinge, Michael Holzer
Journal: Journal of the American College of Cardiology (2017)